Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b. Int J Antimicrob Agents • June 17, 2020
Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line. Int J Antimicrob Agents • May 22, 2020
Can post-exposure prophylaxis for COVID-19 be considered as one of outbreak response strategies in long-term care hospitals? Int J Antimicrob Agents • April 20, 2020
Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents • April 20, 2020
Coronavirus (COVID-19), First Indication of Efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 Infections. Int J Antimicrob Agents • April 14, 2020
Drug repositioning an alternative for the treatment of coronavirus COVID-19. Int J Antimicrob Agents • April 13, 2020
Coronavirus disease 2019 (COVID-19): current status and future perspective. Int J Antimicrob Agents • April 6, 2020
Recent Progress in understanding 2019 Novel Coronavirus associated with Human Respiratory Disease: Detection, Mechanism and Treatment. Int J Antimicrob Agents • April 6, 2020